Algert Global LLC Cuts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Algert Global LLC decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 8.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 950,138 shares of the company’s stock after selling 90,926 shares during the quarter. Algert Global LLC owned about 0.30% of Amneal Pharmaceuticals worth $9,511,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in AMRX. Comerica Bank boosted its position in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the period. Rafferty Asset Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 22.0% during the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock valued at $137,000 after buying an additional 3,066 shares during the period. Exchange Traded Concepts LLC acquired a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $31,000. SG Americas Securities LLC lifted its position in Amneal Pharmaceuticals by 3.5% during the 2nd quarter. SG Americas Securities LLC now owns 99,129 shares of the company’s stock worth $802,000 after acquiring an additional 3,368 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Amneal Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 94,012 shares of the company’s stock worth $941,000 after acquiring an additional 4,125 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on AMRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Barclays started coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. Finally, Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Stock Down 2.3%

Shares of AMRX opened at $11.83 on Monday. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 51.44 and a beta of 1.34. The business’s 50 day moving average is $13.78 and its two-hundred day moving average is $12.02. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $15.42.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.